FDA Sets Final Trial Requirements for Drugs for Complicated Intra-abdominal Infections

Drug Industry Daily
Trials of drugs targeting complicated intra-abdominal infections should use only drugs that are standard of care as active comparators, the FDA says, and studies should minimize the use of outside antibiotics in trial subjects as much as possible to produce clear, definitive trial results.

To View This Article:


Subscribe To Drug Industry Daily